(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/content-delivery-solution.jpg

Our content delivery solution through CRWE WORLD, CRWE Press Release and CRWE Tubegives corporations and businesses a vehicle to expand their exposure

Content Delivery Solution (Learn More)

ad3

https://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

https://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network!. Increase Visibility, Boost Your Business

www.CRWEPressRelease.com






Breaking: Carvana Boosts Outlook; Bullish View On RAPT Therapeutics

  • August 09th, 2023
  • 374 views

Shares of Carvana Co. (NYSE: CVNA) surged over 5% in pre-market trading following its announcement of an enhanced Q3 2023 outlook. The improvement is attributed to significant advancements in key business drivers and strong early-quarter momentum.

Specifically, Carvana has raised its Q3 adjusted EBITDA view to exceed $75 million, marking a shift from positive adjusted EBITDA.

$CVNA was trading at $47.50 in pre-market, reflecting a substantial increase of $3.49 (+7.93%).

In other news, RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company, received positive attention from Stifel as the investment banking firm initiated coverage with a Buy rating and a price target of $40.

Closing at $22.58 on Tuesday, this suggests a potential upside of $17.42 or approximately 77.03% for $RAPT, according to Stifel's assessment.

 

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)

Tags

Social Shares

Post Your Comments

Want To Find Some News?

Recent Posts

News By Industries

Tags